SCHEMBL715520

SCHEMBL715520

Cc1nc(N)nc(N[C@@H](C)c2cc3cccc(C)c3nc2N2CCOCC2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 3/20 0.46
OPRK1 P41145 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
KDM4E B2RXH2 3/20 0.41
PIK3C2B O00750 2/20 0.40
ALDH1A1 P00352 3/20 0.39
MAPT P10636 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ALOX15 P16050 2/20 0.39
USP2 O75604 2/20 0.39
NPC1 O15118 1/20 0.39
NR1I2 O75469 1/20 0.39
TP53 P04637 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
HTT P42858 1/20 0.39
TSHR P16473 2/20 0.38
CASP1 P29466 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716189 0.91 TSHR (0.47) PIK3CDKDM4EALDH1A1MAPTSMN1; SMN2
SCHEMBL716959 0.90 PIK3CB (0.39) PIK3CDTSHRSOS1PIK3CBPIK3CG
SCHEMBL15875803 0.88 TSHR (0.38) PIK3CDOPRK1MEN1KMT2AKDM4E
SCHEMBL715604 0.88 PIK3CD (0.47) PIK3CDKDM4EALDH1A1SMN1; SMN2ALOX15
SCHEMBL15875870 0.87 PIK3CB (0.39) PIK3CDTSHRSOS1PIK3CBPIK3CG
SCHEMBL715553 0.87 PIK3CB (0.39) PIK3CDTSHRSOS1PIK3CBPIK3CG
SCHEMBL714335 0.87 PIK3CD (0.42) PIK3CDMEN1KMT2AKDM4EALDH1A1
SCHEMBL714336 0.87 PIK3CD (0.42) PIK3CDMEN1KMT2AKDM4EALDH1A1
SCHEMBL717467 0.83 PIK3CD (0.41) PIK3CDKDM4EALDH1A1ALOX15USP2
SCHEMBL716805 0.82 PIK3CD (0.40) PIK3CDKDM4EALDH1A1ALOX15USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP claimed
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP disclosed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 PIK3CD 12/4885OPRK1 416/4885MEN1 3000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.